Strong financial results in the first half of 2008 (preliminary figures)July 17, 2008
Bad Homburg v.d.H.
Below, Fresenius provides an overview on the financial results of the first half of 2008:
Based on preliminary figures, Group sales increased 9 % in constant currency and by 2 % at actual rates to € 5,710 million. Group EBIT rose by 8 % in constant currency. At actual rates, EBIT was at previous year’s level of € 780 million. Group net income grew by 13 % in constant currency and by 8 % at actual rates to € 211 million.
Below are the financial results by business segment, based on preliminary figures:
Fresenius Medical Care achieved sales growth of 10 % to US$ 5,177 million. EBIT rose 8 % to US$ 816 million. Net income grew by 17 % to US$ 395 million.
Fresenius Kabi achieved an excellent sales growth of 14 % to € 1,121 million. EBIT increased by 14 % to € 181 million. The EBIT margin was 16.1 % (H1 2007: 16.1 %).
Fresenius Helios achieved strong sales and EBIT growth. Sales increased by 17 % to € 1,040 million. EBIT grew by 22 % to € 83 million.
Fresenius Vamed achieved sales growth of 11 % to € 177 million. EBIT was € 9 million.
The final figures for the first half of 2008 and the outlook for the full year will be provided on July 30, 2008, as originally scheduled.
Key figures of the business segments (US GAAP, preliminary)
This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.
Text as PDF file